Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis
Open Access
- 9 April 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (3), 236-244
- https://doi.org/10.1016/j.clcc.2021.04.001
Abstract
No abstract availableKeywords
Funding Information
- Cancer Research UK
This publication has 34 references indexed in Scilit:
- Swedish experience-based value sets for EQ-5D health statesQuality of Life Research, 2013
- Time Trade-Off Derived EQ-5D Weights for AustraliaValue in Health, 2011
- Productivity Savings from Colorectal Cancer Prevention and Control StrategiesAmerican Journal of Preventive Medicine, 2011
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force ReportValue in Health, 2009
- Generation of a Danish TTO value set for EQ-5D health statesScandinavian Journal of Public Health, 2009
- Oxaliplatin Combined With Weekly Bolus Fluorouracil and Leucovorin As Surgical Adjuvant Chemotherapy for Stage II and III Colon Cancer: Results From NSABP C-07Journal of Clinical Oncology, 2007
- Multinational clinical trials in oncology and post-trial benefits for host countries: where do we stand?European Journal of Cancer, 2006
- Conducting economic evaluations alongside multinational clinical trials: Toward a research consensusAmerican Heart Journal, 2005
- Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdleBMJ, 2004
- Logical inconsistencies in survey respondents' health state valuations ‐ a methodological challenge for estimating social tariffsHealth Economics, 2002